Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial

Objective Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain disorder in children and adolescents for which there are no evidence‐based treatments. The objective of this multisite, single‐blind, randomized clinical trial was to test whether cognitive–behavioral therapy (CBT) was...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & rheumatology (Hoboken, N.J.) Vol. 64; no. 1; pp. 297 - 305
Main Authors: Kashikar-Zuck, Susmita, Ting, Tracy V., Arnold, Lesley M., Bean, Judy, Powers, Scott W., Graham, T. Brent, Passo, Murray H., Schikler, Kenneth N., Hashkes, Philip J., Spalding, Steven, Lynch-Jordan, Anne M., Banez, Gerard, Richards, Margaret M., Lovell, Daniel J.
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-01-2012
Wiley
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain disorder in children and adolescents for which there are no evidence‐based treatments. The objective of this multisite, single‐blind, randomized clinical trial was to test whether cognitive–behavioral therapy (CBT) was superior to fibromyalgia (FM) education in reducing functional disability, pain, and symptoms of depression in juvenile FMS. Methods Participants were 114 adolescents (ages 11–18 years) with juvenile FMS. After receiving stable medications for 8 weeks, patients were randomized to either CBT or FM education and received 8 weekly individual sessions with a therapist and 2 booster sessions. Assessments were conducted at baseline, immediately following the 8‐week treatment phase, and at 6‐month followup. Results The majority of patients (87.7%) completed the trial per protocol. Intent‐to‐treat analyses showed that patients in both groups had significant reductions in functional disability, pain, and symptoms of depression at the end of the study, and CBT was significantly superior to FM education in reducing the primary outcome of functional disability (mean baseline to end‐of‐treatment difference between groups 5.39 [95% confidence interval 1.57, 9.22]). Reduction in symptoms of depression was clinically significant for both groups, with mean scores in the range of normal/nondepressed by the end of the study. Reduction in pain was not clinically significant for either group (<30% decrease in pain). There were no study‐related adverse events. Conclusion In this controlled trial, CBT was found to be a safe and effective treatment for reducing functional disability and symptoms of depression in adolescents with juvenile FMS.
Bibliography:ark:/67375/WNG-CR9LL4B4-S
ClinicalTrials.gov identifier: NCT00086047.
ArticleID:ART30644
NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) - No. R01-AR-050028
istex:12D81F85E2178D8337992FCADB25EB9A11018E8F
Dr. Passo has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than $10,000).
identifier: NCT00086047.
ClinicalTrials.gov
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:0004-3591
2326-5191
1529-0131
2326-5205
DOI:10.1002/art.30644